APP and Alzheimer disease: No additional in vivo tests were performed to evaluate treatment efficacy in the context of AD (György et al., 2018; Sun et al., 2019), but these therapeutic strategies targeting the C-terminal part of APP are of interest because the aim was to attenuate pathological properties (Aβ generation) while potentially maintaining Duarte and Déglon Corrigendum: Genome Editing for CNS Disorders other physiological functions of APP.